Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of nelfinavir in preparation of medicine for preventing and treating COVID-19

A technology of nelfinavir and drugs, which is applied in the application field of nelfinavir in the preparation of drugs for the prevention and treatment of new coronary pneumonia, which can solve the problems of human-to-human infection, virus transmission route not fully grasped, virus mutation, etc.

Pending Publication Date: 2021-08-17
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +3
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The transmission route of 2019-nCoV virus has not been fully grasped. It is known that it can be transmitted through droplets and contact, and there is human-to-human transmission and medical staff infection. There is a certain risk of community transmission, and the virus may mutate
[0006] Currently, there is no effective vaccine or antiviral drug for severe pneumonia caused by 2019-nCoV coronavirus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nelfinavir in preparation of medicine for preventing and treating COVID-19
  • Application of nelfinavir in preparation of medicine for preventing and treating COVID-19
  • Application of nelfinavir in preparation of medicine for preventing and treating COVID-19

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] Example 1: Nelfinavir against 2019-nCoV M pro Computational Simulation of Proteases

[0102] Using 2GX4 as a template, using SWISS-MODEL to model 2019-nCoV M pro For the three-dimensional structure of protease, nelfinavir is docked into it, and the docking score is -9.18kcal / mol. The three-dimensional similarity with the binding mode of the ligand TG-0205221 in 2GX4 and the target protein is 70.2%.

[0103] The result is as figure 1 shown. This result shows that nelfinavir can be compared with 2019-nCoV M in computational simulation. pro Proteases bind well and have binding patterns with high confidence.

[0104] The docking complex was simulated using Amber16 for 5 nanoseconds of molecular dynamics, and then the binding free energy was calculated using the MM / GBSA and SIE methods, and the obtained energies were -24.69±0.52 kcal / mol and -9.42±0.04 kcal / mol, respectively, The specific results are listed in Table 1 and Table 2.

[0105] Nelfinavir and 2019-nCoV M ca...

Embodiment 2

[0114] Example 2: Nelfinavir against 2019-nCoV M pro Experimental Tests for Proteases

[0115] In this example, the determination of compounds against 2019-nCoV M pro Protease (SARS-CoV-2 3CLpro) inhibitory activity, the method is: use fluorescence resonance energy transfer (fluorescence resonance energy transferFRET) technology to measure the enzyme level inhibitory activity of the inhibitor against 3CL protease. The volume of the entire enzymatic reaction system is 120 μL, the final concentration of protease is 30 nM, and the final concentration of substrate is 20 μM. The buffer of the reaction system includes 50 mM Tris pH7.3, 1 mM EDTA. Add the 2019 novel coronavirus (2019-nCoV) 3CL protease and different concentrations of test compounds to the 96-well plate, incubate at 30°C for 10 minutes, add the substrate and quickly put it into a microplate reader for reading. Excitation light and emission light are 320nm and 405nm, respectively. The test time was 10min, and the f...

Embodiment 3

[0121] Example 3: Inhibition experiment of nelfinavir on 2019-nCoV at the cellular level

[0122] Using the African green monkey kidney cell Vero as a model, in a 24-well culture plate, after infecting the cells with 100TCID50 of the 2019 novel coronavirus strain for 3 hours, the culture medium containing the virus was discarded, and the cells were washed twice with PBS, and then added with different concentrations of The culture medium of the drug was continued for 48 hours. Then the cell culture supernatant was aspirated, the virus nucleic acid was extracted by the magnetic bead method, and the virus content in the cell culture medium of the nelfinavir treatment group was analyzed using the new coronavirus fluorescent quantitative PCR kit.

[0123] The result is as figure 2 , image 3 and shown in Table 4.

[0124] Table 4. The results of in vitro antiviral experiments (cell experiments) of nelfinavir mesylate

[0125]

[0126] Such as figure 2 As shown in Table 3,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Therapeutic indexaaaaaaaaaa
Login to View More

Abstract

The invention relates to application of nelfinavir in preparation of a medicine for preventing and treating COVID-19. Specifically, the invention relates to application of nelfinavir and a pharmaceutical composition thereof as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) inhibitor in preparation of drugs for treating and / or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019-nCoV infection.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of nelfinavir in the preparation of drugs for the prevention and treatment of new coronary pneumonia. Background technique [0002] Among the acute infectious diseases, most of them are viral infectious diseases, and the incidence rate of viral infectious diseases is high, and the mortality rate is also high. Due to the limited means of detection and diagnosis, outbreaks of new outbreaks caused by new viruses are often characterized by suddenness, randomness, and unpredictability. Health and life safety. [0003] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019 novel coronavirus, 2019-nCoV) infection can cause novel coronavirus pneumonia (coronavirus disease 2019, COVID-19). The transmission route of 2019-nCoV virus has not been fully grasped. It is known that it can be transmitted through droplets and contact, and there is human-to-human transmission ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/472A61K45/06A61K31/4965A61K31/4706A61P31/14A61P11/00
CPCA61K31/472A61K45/06A61K31/4965A61K31/4706A61P31/14A61P11/00A61K2300/00
Inventor 徐志建姚航平许叶春吴南屏彭诚郑敏卢翔云苏海霞程林芳刘福民吴海波靳昌忠吴志刚沈敬山朱维良蒋华良李兰娟郑永唐韩建保宋天章冯小丽田仁荣李川杨军令宫丽崑吴春晖蒋翔锐王震
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com